This bibliography shows the most interesting papers selected from pmc PubMedCentral which were newly included in covid008I
It is available online and for download at http://www.kidney.de/write/PMCmedVIP_covid008I.html
Skewed: Nephrology, Rheumatology, Immunology, Cell Biology, Research Methods. on-topic and educational Clinical Medicine.
The full table of all monthly collections is: at house-of-papers.com
PMC searches were done at moremed.org





{{tp|p=32525657|t=2020. Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia.|pdf=|usr=}}
{{tp|p=32463221|t=2020. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients.|pdf=|usr=}}
{{tp|p=32503680|t=2020. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.|pdf=|usr=}}
{{tp|p=32503668|t=2020. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients.|pdf=|usr=}}
{{tp|p=32412156|t=2020. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.|pdf=|usr=}}
{{tp|p=32398307|t=2020. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.|pdf=|usr=}}
{{tp|p=32379368|t=2020. Gastrointestinal effects of an attempt to "disinfect" from COVID-19.|pdf=|usr=}}
{{tp|p=32398162|t=2020. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission.|pdf=|usr=}}
{{tp|p=32498696|t=2020. COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice.|pdf=|usr=}}
{{tp|p=32461409|t=2020. Sanitizer aerosol-driven ocular surface disease (SADOSD)-A COVID-19 repercussion?|pdf=|usr=}}
{{tp|p=32519263|t=2020. India's COVID-19 Testing Strategy: Why Pediatric Hospitals Need to Focus More on ILI than SARI?|pdf=|usr=}}
{{tp|p=32277747|t=2020. A Low-cost Solution for Retro-fitment of HEPA Filter in Healthcare Facilities Providing Care to COVID-19 Patients.|pdf=|usr=}}
{{tp|p=32381129|t=2020. Dealing with skin reactions to gloves during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=32456749|t=2020. Filtration evaluation and clinical use of expired elastomeric P-100 filter cartridges during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=32408923|t=2020. Facepiece filtering respirators with exhalation valve should not be used in the community to limit SARS-CoV-2 diffusion.|pdf=|usr=}}
{{tp|p=32459123|t=2020. Mechanistic inferences from clinical reports of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32474804|t=2020. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.|pdf=|usr=}}
{{tp|p=32468178|t=2020. Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.|pdf=|usr=}}
{{tp|p=32399895|t=2020. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.|pdf=|usr=}}
{{tp|p=32492530|t=2020. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.|pdf=|usr=}}
{{tp|p=32470604|t=2020. A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response.|pdf=|usr=}}
{{tp|p=32464271|t=2020. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?|pdf=|usr=}}
{{tp|p=32425643|t=2020. Association of inflammatory markers with the severity of COVID-19: A meta-analysis.|pdf=|usr=}}
{{tp|p=32425634|t=2020. The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=32422376|t=2020. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.|pdf=|usr=}}
{{tp|p=32437933|t=2020. Viral dynamics in asymptomatic patients with COVID-19.|pdf=|usr=}}
{{tp|p=32437934|t=2020. Use of anakinra in severe COVID-19: a case report.|pdf=|usr=}}
{{tp|p=32497811|t=2020. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?|pdf=|usr=}}
{{tp|p=32497810|t=2020. HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL TRIALS OF MASKS AND RESPIRATORS.|pdf=|usr=}}
{{tp|p=32504146|t=2020. Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation.|pdf=|usr=}}
{{tp|p=32500199|t=2020. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.|pdf=|usr=}}
{{tp|p=32458044|t=2020. Inside the lungs of COVID-19 disease.|pdf=|usr=}}
{{tp|p=32397684|t=2020. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.|pdf=|usr=}}
{{tp|p=32397010|t=2020. N95 respirator associated pressure ulcer amongst COVID-19 health care workers.|pdf=|usr=}}
{{tp|p=32396265|t=2020. The prevalence, characteristics, and related factors of pressure injury in medical staff wearing personal protective equipment against COVID-19 in China: A multicentre cross-sectional survey.|pdf=|usr=}}
{{tp|p=32385523|t=2020. IL-6 may be a good biomarker for earlier detection of COVID-19 progression.|pdf=|usr=}}
{{tp|p=32424481|t=2020. Stages or phenotypes? A critical look at COVID-19 pathophysiology.|pdf=|usr=}}
{{tp|p=32424480|t=2020. Contrast-enhanced ultrasound (CEUS) of the lung reveals multiple areas of microthrombi in a COVID-19 patient.|pdf=|usr=}}
{{tp|p=32514592|t=2020. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.|pdf=|usr=}}
{{tp|p=32504103|t=2020. Ten things we learned about COVID-19.|pdf=|usr=}}
{{tp|p=32494929|t=2020. COVID-19: 10 things I wished I'd known some months ago.|pdf=|usr=}}
{{tp|p=32494927|t=2020. Histological-ultrasonographical correlation of pulmonary involvement in severe COVID-19.|pdf=|usr=}}
{{tp|p=32488341|t=2020. Rethinking the respiratory paradigm of COVID-19: a 'hole' in the argument.|pdf=|usr=}}
{{tp|p=32533198|t=2020. Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection.|pdf=|usr=}}
{{tp|p=32430651|t=2020. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.|pdf=|usr=}}
{{tp|p=32415560|t=2020. Bronchoalveolar lavage findings in severe COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=32399954|t=2020. SARS-CoV-2 and myocardial injury: a role for Nox2?|pdf=|usr=}}
{{tp|p=32405622|t=2020. The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike.|pdf=|usr=}}
{{tp|p=32389590|t=2020. COVID-19: Unanswered questions on immune response and pathogenesis.|pdf=|usr=}}
{{tp|p=32425269|t=2020. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.|pdf=|usr=}}
{{tp|p=32422146|t=2020. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.|pdf=|usr=}}
{{tp|p=32422144|t=2020. Perforin and resistance to SARS coronavirus 2.|pdf=|usr=}}
{{tp|p=32417135|t=2020. Complement activation in patients with COVID-19: A novel therapeutic target.|pdf=|usr=}}
{{tp|p=32413374|t=2020. Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective.|pdf=|usr=}}
{{tp|p=32437740|t=2020. The immunologic status of newborns born to SARS-CoV-2-infected mothers in Wuhan, China.|pdf=|usr=}}
{{tp|p=32407836|t=2020. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.|pdf=|usr=}}
{{tp|p=32531372|t=2020. Expression of SARS-CoV-2 Receptor ACE2 and Coincident Host Response Signature Varies by Asthma Inflammatory Phenotype.|pdf=|usr=}}
{{tp|p=32416206|t=2020. COVID-19 and personal protective equipment: Treatment and prevention of skin conditions related to the occupational use of personal protective equipment.|pdf=|usr=}}
{{tp|p=32417418|t=2020. Reply to: "Skin damage among health care workers managing coronavirus disease 2019".|pdf=|usr=}}
{{tp|p=32498686|t=2020. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=32515358|t=2020. Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility.|pdf=|usr=}}
{{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=}}
{{tp|p=32406037|t=2020. COVID-19: is fibrosis the killer?|pdf=|usr=}}
{{tp|p=32473501|t=2020. Respirators used by healthcare workers due to the COVID-19 outbreak increase end-tidal carbon dioxide and fractional inspired carbon dioxide pressure.|pdf=|usr=}}
{{tp|p=32510470|t=2020. Is innate immunity our best weapon for flattening the curve?|pdf=|usr=}}
{{tp|p=32430154|t=2020. Hypolipidemia is associated with the severity of COVID-19.|pdf=|usr=}}
{{tp|p=32434770|t=2020. Predictive molecular pathology in the time of COVID-19.|pdf=|usr=}}
{{tp|p=32283335|t=2020. ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease.|pdf=|usr=}}
{{tp|p=32361326|t=2020. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.|pdf=|usr=}}
{{tp|p=32464309|t=2020. Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients.|pdf=|usr=}}
{{tp|p=32425659|t=2020. Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design.|pdf=|usr=}}
{{tp|p=32451971|t=2020. Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?|pdf=|usr=}}
{{tp|p=32398780|t=2020. The role of the exposome in promoting resilience or susceptibility after SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=32456973|t=2020. The novel coronavirus (COVID-19) and the risk of Kawasaki disease in children.|pdf=|usr=}}
{{tp|p=32366279|t=2020. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis.|pdf=|usr=}}
{{tp|p=32437830|t=2020. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.|pdf=|usr=}}
{{tp|p=32385146|t=2020. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.|pdf=|usr=}}
{{tp|p=32442454|t=2020. Which cancer type has the highest risk of COVID-19 infection?|pdf=|usr=}}
{{tp|p=32417316|t=2020. Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19.|pdf=|usr=}}
{{tp|p=32417310|t=2020. Characterization of eight novel full-length genomes of SARS-CoV-2 among imported COVID-19 cases from abroad in Yunnan, China.|pdf=|usr=}}
{{tp|p=32526326|t=2020. Interleukin-6 as prognosticator in patients with COVID-19.|pdf=|usr=}}
{{tp|p=32525000|t=2020. Aspartate aminotransferase: A prognostic marker rather than a specific liver injury marker in COVID-19.|pdf=|usr=}}
{{tp|p=32534002|t=2020. Cancer population may be paradoxically protected from severe manifestations of COVID-19.|pdf=|usr=}}
{{tp|p=32283152|t=2020. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.|pdf=|usr=}}
{{tp|p=32283146|t=2020. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy.|pdf=|usr=}}
{{tp|p=32360499|t=2020. Comparative seasonalities of influenza A, B and 'common cold' coronaviruses - setting the scene for SARS-CoV-2 infections and possible unexpected host immune interactions.|pdf=|usr=}}
{{tp|p=32283147|t=2020. Prolonged virus shedding even after seroconversion in a patient with COVID-19.|pdf=|usr=}}
{{tp|p=32534944|t=2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.|pdf=|usr=}}
{{tp|p=32483488|t=2020. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=32454066|t=2020. High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32461703|t=2020. Mechanobiology predicts raft formations triggered by ligand-receptor activity across the cell membrane.|pdf=|usr=}}
{{tp|p=32383269|t=2020. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.|pdf=|usr=}}
{{tp|p=32383254|t=2020. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples.|pdf=|usr=}}
{{tp|p=32383183|t=2020. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.|pdf=|usr=}}
{{tp|p=32410229|t=2020. Evidence of Increasing Diversification of Emerging SARS-CoV-2 Strains.|pdf=|usr=}}
{{tp|p=32406952|t=2020. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity.|pdf=|usr=}}
{{tp|p=32401345|t=2020. Genetic variants and source of introduction of SARS-CoV-2 in South America.|pdf=|usr=}}
{{tp|p=32181903|t=2020. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19.|pdf=|usr=}}
{{tp|p=32159234|t=2020. Identification of coronavirus sequences in carp cDNA from Wuhan, China.|pdf=|usr=}}
{{tp|p=32519779|t=2020. Circulating levels of IL-2, IL-4, TNF-alpha, IFN-gamma, and C-reactive protein are not associated with severity of COVID-19 symptoms.|pdf=|usr=}}
{{tp|p=32242950|t=2020. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.|pdf=|usr=}}
{{tp|p=32471659|t=2020. Silencing of immune activation with methotrexate in patients with COVID-19.|pdf=|usr=}}
{{tp|p=32534807|t=2020. Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack.|pdf=|usr=}}
{{tp|p=32452979|t=2020. Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab.|pdf=|usr=}}
{{tp|p=32392072|t=2020. Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks.|pdf=|usr=}}
{{tp|p=32463239|t=2020. Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations.|pdf=|usr=}}
{{tp|p=32521376|t=2020. SARS-CoV-2 (Covid-19): Interferon-epsilon may be responsible of decreased mortality in females.|pdf=|usr=}}
{{tp|p=32514817|t=2020. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32525700|t=2020. Multi-System Inflammatory Syndrome in Children in Association with COVID-19.|pdf=|usr=}}
{{tp|p=32521002|t=2020. Antibody profiles in mild and severe cases of COVID-19.|pdf=|usr=}}
{{tp|p=32522846|t=2020. ACE2 and COVID-19 and the resulting ARDS.|pdf=|usr=}}
{{tp|p=32522874|t=2020. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses.|pdf=|usr=}}

PMC7299394 1. Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia.

ACS Chem Neurosci 2020; ä (ä): ä

*32525657*
                       32525657

PMC7263077 2. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients.

ACS Infect Dis 2020; ä (ä): ä

*32463221*
                       32463221

PMC7273814 3. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.

Crit Care 2020; 24 (1): 290

*32503680*
                       32503680

PMC7273815 4. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients.

Crit Care 2020; 24 (1): 288

*32503668*
                       32503668

PMC7273093 5. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.

Eur J Heart Fail 2020; ä (ä): ä

*32412156*
                       32412156

PMC7236821 6. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.

Eur Respir J 2020; ä (ä): ä

*32398307*
                       32398307

PMC7267257 7. Gastrointestinal effects of an attempt to "disinfect" from COVID-19.

Histopathology 2020; ä (ä): ä

*32379368*
                       32379368

PMC7214856 8. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission.

Hum Genomics 2020; 14 (1): 17

*32398162*
                       32398162

PMC7269898 9. COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice.

Hum Genomics 2020; 14 (1): 20

*32498696*
                       32498696

10. Sanitizer aerosol-driven ocular surface disease (SADOSD)-A COVID-19 repercussion?

Indian J Ophthalmol 2020; 68 (6): 981-983

*32461409*
                       32461409

PMC7282887 11. India's COVID-19 Testing Strategy: Why Pediatric Hospitals Need to Focus More on ILI than SARI?

Indian J Pediatr 2020; ä (ä): ä

*32519263*
                       32519263

PMC7240234 12. A Low-cost Solution for Retro-fitment of HEPA Filter in Healthcare Facilities Providing Care to COVID-19 Patients.

Indian Pediatr 2020; 57 (5): 477

*32277747*
                       32277747

PMC7231665 13. Dealing with skin reactions to gloves during the COVID-19 pandemic.

Infect Control Hosp Epidemiol 2020; ä (ä): 1-2

*32381129*
                       32381129

PMC7272694 14. Filtration evaluation and clinical use of expired elastomeric P-100 filter cartridges during the COVID-19 pandemic.

Infect Control Hosp Epidemiol 2020; ä (ä): 1-2

*32456749*
                       32456749

PMC7253762 15. Facepiece filtering respirators with exhalation valve should not be used in the community to limit SARS-CoV-2 diffusion.

Infect Control Hosp Epidemiol 2020; ä (ä): 1-2

*32408923*
                       32408923

PMC7265107 16. Mechanistic inferences from clinical reports of SARS-CoV-2.

Infect Dis (Lond) 2020; 52 (8): 527-537

*32459123*
                       32459123

PMC7261214 17. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.

Int J Hematol 2020; 112 (1): 125-126

*32474804*
                       32474804

PMC7255442 18. Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.

Int J Hematol 2020; 112 (1): 127

*32468178*
                       32468178

PMC7216850 19. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.

Int J Hematol 2020; 112 (1): 122-124

*32399895*
                       32399895

PMC7261468 20. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.

Int J Infect Dis 2020; ä (ä): ä

*32492530*
                       32492530

PMC7250069 21. A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response.

Int J Infect Dis 2020; 96 (ä): 464-466

*32470604*
                       32470604

PMC7247990 22. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?

Int J Infect Dis 2020; 96 (ä): 459-460

*32464271*
                       32464271

PMC7233226 23. Association of inflammatory markers with the severity of COVID-19: A meta-analysis.

Int J Infect Dis 2020; 96 (ä): 467-474

*32425643*
                       32425643

PMC7231485 24. The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection.

Int J Infect Dis 2020; 96 (ä): 359-360

*32425634*
                       32425634

PMC7228890 25. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.

Int J Infect Dis 2020; ä (ä): ä

*32422376*
                       32422376

PMC7211726 26. Viral dynamics in asymptomatic patients with COVID-19.

Int J Infect Dis 2020; 96 (ä): 288-290

*32437933*
                       32437933

PMC7211644 27. Use of anakinra in severe COVID-19: a case report.

Int J Infect Dis 2020; ä (ä): ä

*32437934*
                       32437934

PMC7264936 28. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?

Int J Infect Dis 2020; ä (ä): ä

*32497811*
                       32497811

PMC7263249 29. HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL TRIALS OF MASKS AND RESPIRATORS.

Int J Infect Dis 2020; ä (ä): ä

*32497810*
                       32497810

PMC7273129 30. Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation.

Int J Legal Med 2020; 134 (4): 1285-1290

*32504146*
                       32504146

PMC7271136 31. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.

Int J Legal Med 2020; 134 (4): 1275-1284

*32500199*
                       32500199

PMC7248187 32. Inside the lungs of COVID-19 disease.

Int J Legal Med 2020; 134 (4): 1271-1274

*32458044*
                       32458044

PMC7247005 33. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.

Int J Mol Sci 2020; 21 (9): ä

*32397684*
                       32397684

PMC7272882 34. N95 respirator associated pressure ulcer amongst COVID-19 health care workers.

Int Wound J 2020; ä (ä): ä

*32397010*
                       32397010

PMC7273008 35. The prevalence, characteristics, and related factors of pressure injury in medical staff wearing personal protective equipment against COVID-19 in China: A multicentre cross-sectional survey.

Int Wound J 2020; ä (ä): ä

*32396265*
                       32396265

PMC7206216 36. IL-6 may be a good biomarker for earlier detection of COVID-19 progression.

Intensive Care Med 2020; ä (ä): ä

*32385523*
                       32385523

PMC7232601 37. Stages or phenotypes? A critical look at COVID-19 pathophysiology.

Intensive Care Med 2020; ä (ä): ä

*32424481*
                       32424481

PMC7232610 38. Contrast-enhanced ultrasound (CEUS) of the lung reveals multiple areas of microthrombi in a COVID-19 patient.

Intensive Care Med 2020; ä (ä): ä

*32424480*
                       32424480

PMC7276497 39. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.

Intensive Care Med 2020; ä (ä): ä

*32514592*
                       32514592

PMC7273118 40. Ten things we learned about COVID-19.

Intensive Care Med 2020; ä (ä): ä

*32504103*
                       32504103

PMC7268592 41. COVID-19: 10 things I wished I'd known some months ago.

Intensive Care Med 2020; ä (ä): ä

*32494929*
                       32494929

PMC7266913 42. Histological-ultrasonographical correlation of pulmonary involvement in severe COVID-19.

Intensive Care Med 2020; ä (ä): ä

*32494927*
                       32494927

PMC7264482 43. Rethinking the respiratory paradigm of COVID-19: a 'hole' in the argument.

Intensive Care Med 2020; ä (ä): ä

*32488341*
                       32488341

PMC7291173 44. Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection.

Intensive Care Med 2020; ä (ä): ä

*32533198*
                       32533198

PMC7236433 45. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.

Intern Emerg Med 2020; ä (ä): ä

*32430651*
                       32430651

PMC7225401 46. Bronchoalveolar lavage findings in severe COVID-19 pneumonia.

Intern Emerg Med 2020; ä (ä): ä

*32415560*
                       32415560

PMC7214847 47. SARS-CoV-2 and myocardial injury: a role for Nox2?

Intern Emerg Med 2020; ä (ä): ä

*32399954*
                       32399954

PMC7219414 48. The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike.

iScience 2020; 23 (6): 101160

*32405622*
                       32405622

PMC7205667 49. COVID-19: Unanswered questions on immune response and pathogenesis.

J Allergy Clin Immunol 2020; ä (ä): ä

*32389590*
                       32389590

PMC7233239 50. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.

J Allergy Clin Immunol 2020; ä (ä): ä

*32425269*
                       32425269

PMC7227558 51. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.

J Allergy Clin Immunol 2020; ä (ä): ä

*32422146*
                       32422146

PMC7255292 52. Perforin and resistance to SARS coronavirus 2.

J Allergy Clin Immunol 2020; ä (ä): ä

*32422144*
                       32422144

PMC7224678 53. Complement activation in patients with COVID-19: A novel therapeutic target.

J Allergy Clin Immunol 2020; ä (ä): ä

*32417135*
                       32417135

PMC7215168 54. Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective.

J Allergy Clin Immunol 2020; ä (ä): ä

*32413374*
                       32413374

PMC7211641 55. The immunologic status of newborns born to SARS-CoV-2-infected mothers in Wuhan, China.

J Allergy Clin Immunol 2020; ä (ä): ä

*32437740*
                       32437740

PMC7212968 56. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.

J Allergy Clin Immunol 2020; ä (ä): ä

*32407836*
                       32407836

PMC7283064 57. Expression of SARS-CoV-2 Receptor ACE2 and Coincident Host Response Signature Varies by Asthma Inflammatory Phenotype.

J Allergy Clin Immunol 2020; ä (ä): ä

*32531372*
                       32531372

PMC7228687 58. COVID-19 and personal protective equipment: Treatment and prevention of skin conditions related to the occupational use of personal protective equipment.

J Am Acad Dermatol 2020; ä (ä): ä

*32416206*
                       32416206

PMC7224676 59. Reply to: "Skin damage among health care workers managing coronavirus disease 2019".

J Am Acad Dermatol 2020; ä (ä): ä

*32417418*
                       32417418

PMC7270518 60. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).

J Biomed Sci 2020; 27 (1): 72

*32498686*
                       32498686

PMC7269891 61. Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility.

J Biosci 2020; 45 (ä): ä

*32515358*
                       32515358

PMC7250255 62. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.

J Cardiovasc Transl Res 2020; ä (ä): ä

*32458400*
                       32458400

PMC7220615 63. COVID-19: is fibrosis the killer?

J Cell Commun Signal 2020; 14 (2): 255

*32406037*
                       32406037

PMC7242931 64. Respirators used by healthcare workers due to the COVID-19 outbreak increase end-tidal carbon dioxide and fractional inspired carbon dioxide pressure.

J Clin Anesth 2020; 66 (ä): 109901

*32473501*
                       32473501

65. Is innate immunity our best weapon for flattening the curve?

J Clin Invest 2020; ä (ä): ä

*32510470*
                       32510470

PMC7192140 66. Hypolipidemia is associated with the severity of COVID-19.

J Clin Lipidol 2020; 14 (3): 297-304

*32430154*
                       32430154

PMC7242869 67. Predictive molecular pathology in the time of COVID-19.

J Clin Pathol 2020; ä (ä): ä

*32434770*
                       32434770

PMC7129721 68. ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease.

J Clin Virol 2020; 126 (ä): 104350

*32283335*
                       32283335

69. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.

J Clin Virol 2020; 127 (ä): 104388

*32361326*
                       32361326

PMC7237947 70. Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients.

J Clin Virol 2020; 128 (ä): 104450

*32464309*
                       32464309

PMC7227581 71. Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design.

J Clin Virol 2020; 128 (ä): 104441

*32425659*
                       32425659

PMC7246958 72. Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?

J Endocrinol Invest 2020; ä (ä): ä

*32451971*
                       32451971

PMC7216860 73. The role of the exposome in promoting resilience or susceptibility after SARS-CoV-2 infection.

J Expo Sci Environ Epidemiol 2020; ä (ä): ä

*32398780*
                       32398780

PMC7245250 74. The novel coronavirus (COVID-19) and the risk of Kawasaki disease in children.

J Formos Med Assoc 2020; ä (ä): ä

*32456973*
                       32456973

PMC7197362 75. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis.

J Hematol Oncol 2020; 13 (1): 43

*32366279*
                       32366279

PMC7211738 76. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.

J Hepatol 2020; ä (ä): ä

*32437830*
                       32437830

PMC7211108 77. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.

J Immunother Cancer 2020; 8 (1): ä

*32385146*
                       32385146

PMC7235576 78. Which cancer type has the highest risk of COVID-19 infection?

J Infect 2020; ä (ä): ä

*32442454*
                       32442454

PMC7228739 79. Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19.

J Infect 2020; ä (ä): ä

*32417316*
                       32417316

PMC7228736 80. Characterization of eight novel full-length genomes of SARS-CoV-2 among imported COVID-19 cases from abroad in Yunnan, China.

J Infect 2020; ä (ä): ä

*32417310*
                       32417310

PMC7278637 81. Interleukin-6 as prognosticator in patients with COVID-19.

J Infect 2020; ä (ä): ä

*32526326*
                       32526326

PMC7276226 82. Aspartate aminotransferase: A prognostic marker rather than a specific liver injury marker in COVID-19.

J Infect 2020; ä (ä): ä

*32525000*
                       32525000

PMC7286269 83. Cancer population may be paradoxically protected from severe manifestations of COVID-19.

J Infect 2020; ä (ä): ä

*32534002*
                       32534002

PMC7194613 84. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.

J Infect 2020; 80 (6): 607-613

*32283152*
                       32283152

PMC7195303 85. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy.

J Infect 2020; 81 (1): e24-e27

*32283146*
                       32283146

PMC7189195 86. Comparative seasonalities of influenza A, B and 'common cold' coronaviruses - setting the scene for SARS-CoV-2 infections and possible unexpected host immune interactions.

J Infect 2020; ä (ä): ä

*32360499*
                       32360499

PMC7151379 87. Prolonged virus shedding even after seroconversion in a patient with COVID-19.

J Infect 2020; ä (ä): ä

*32283147*
                       32283147

PMC7275989 88. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.

J Infect Public Health 2020; ä (ä): ä

*32534944*
                       32534944

PMC7245646 89. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.

J Intensive Care 2020; 8 (ä): 36

*32483488*
                       32483488

PMC7245327 90. High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2.

J Invest Dermatol 2020; ä (ä): ä

*32454066*
                       32454066

PMC7243794 91. Mechanobiology predicts raft formations triggered by ligand-receptor activity across the cell membrane.

J Mech Phys Solids 2020; 141 (ä): 103974

*32461703*
                       32461703

PMC7267663 92. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.

J Med Virol 2020; ä (ä): ä

*32383269*
                       32383269

PMC7267461 93. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples.

J Med Virol 2020; ä (ä): ä

*32383254*
                       32383254

PMC7267228 94. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.

J Med Virol 2020; ä (ä): ä

*32383183*
                       32383183

PMC7273070 95. Evidence of Increasing Diversification of Emerging SARS-CoV-2 Strains.

J Med Virol 2020; ä (ä): ä

*32410229*
                       32410229

PMC7273060 96. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity.

J Med Virol 2020; ä (ä): ä

*32406952*
                       32406952

PMC7272973 97. Genetic variants and source of introduction of SARS-CoV-2 in South America.

J Med Virol 2020; ä (ä): ä

*32401345*
                       32401345

PMC7228291 98. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19.

J Med Virol 2020; ä (ä): ä

*32181903*
                       32181903

PMC7228230 99. Identification of coronavirus sequences in carp cDNA from Wuhan, China.

J Med Virol 2020; ä (ä): ä

*32159234*
                       32159234

PMC7300996 100. Circulating levels of IL-2, IL-4, TNF-alpha, IFN-gamma, and C-reactive protein are not associated with severity of COVID-19 symptoms.

J Med Virol 2020; ä (ä): ä

*32519779*
                       32519779

PMC7228336 101. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.

J Med Virol 2020; ä (ä): ä

*32242950*
                       32242950

PMC7247505 102. Silencing of immune activation with methotrexate in patients with COVID-19.

J Neurol Sci 2020; ä (ä): 116942

*32471659*
                       32471659

PMC7241359 103. Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack.

J Neurol Sci 2020; ä (ä): 116935

*32534807*
                       32534807

PMC7268863 104. Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab.

J Pediatr Gastroenterol Nutr 2020; ä (ä): ä

*32452979*
                       32452979

PMC7243427 105. Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks.

J Phys Chem Lett 2020; 11 (11): 4430-4435

*32392072*
                       32392072

PMC7274147 106. Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations.

J Phys Chem Lett 2020; 11 (12): 4785-4790

*32463239*
                       32463239

PMC7265849 107. SARS-CoV-2 (Covid-19): Interferon-epsilon may be responsible of decreased mortality in females.

J Reprod Immunol 2020; 141 (ä): 103154

*32521376*
                       32521376

108. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.

Adv Exp Med Biol 2020; ä (ä): ä

*32514817*
                       32514817

109. Multi-System Inflammatory Syndrome in Children in Association with COVID-19.

Circulation 2020; ä (ä): ä

*32525700*
                       32525700

110. Antibody profiles in mild and severe cases of COVID-19.

Clin Chem 2020; ä (ä): ä

*32521002*
                       32521002

111. ACE2 and COVID-19 and the resulting ARDS.

Postgrad Med J 2020; ä (ä): ä

*32522846*
                       32522846

112. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses.

Proc Natl Acad Sci U S A 2020; ä (ä): ä

*32522874*
                       32522874


{{tp|p=32479986|t=2020. Type 3 hypersensitivity in COVID-19 vasculitis.|pdf=|usr=}}
{{tp|p=32479985|t=2020. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.|pdf=|usr=}}
{{tp|p=32473354|t=2020. Racial disparity in Covid-19 mortality rates - A plausible explanation.|pdf=|usr=}}
{{tp|p=32474885|t=2020. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.|pdf=|usr=}}
{{tp|p=32462425|t=2020. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia.|pdf=|usr=}}
{{tp|p=32399213|t=2020. Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence.|pdf=|usr=}}
{{tp|p=32384917|t=2020. COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review.|pdf=|usr=}}
{{tp|p=32456696|t=2020. COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.|pdf=|usr=}}
{{tp|p=32456658|t=2020. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=32414395|t=2020. COVID-19: room for treating T cell exhaustion?|pdf=|usr=}}
{{tp|p=32410690|t=2020. Age and sex differences in soluble ACE2 may give insights for COVID-19.|pdf=|usr=}}
{{tp|p=32517773|t=2020. Systemic hypoferremia and severity of hypoxemic respiratory failure in COVID-19.|pdf=|usr=}}
{{tp|p=32499988|t=2020. Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines.|pdf=|usr=}}
{{tp|p=32416074|t=2020. A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein.|pdf=|usr=}}
{{tp|p=32460144|t=2020. Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions.|pdf=|usr=}}
{{tp|p=32522400|t=2020. Letter to the Editor on "Bonafe M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev".|pdf=|usr=}}
{{tp|p=32513566|t=2020. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.|pdf=|usr=}}
{{tp|p=32475759|t=2020. IL-6: Relevance for immunopathology of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32446778|t=2020. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.|pdf=|usr=}}
{{tp|p=32389499|t=2020. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes.|pdf=|usr=}}
{{tp|p=32421092|t=2020. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.|pdf=|usr=}}
{{tp|p=32470851|t=2020. Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.|pdf=|usr=}}
{{tp|p=32417709|t=2020. Mechanism of inflammatory response in associated comorbidities in COVID-19.|pdf=|usr=}}
{{tp|p=32517769|t=2020. Histopathology of COVID-19 pneumonia in two non-oncological, non-hospitalised cases as a reliable diagnostic benchmark.|pdf=|usr=}}
{{tp|p=32412125|t=2020. Androgen sensitivity gateway to COVID-19 disease severity.|pdf=|usr=}}
{{tp|p=32454408|t=2020. COVID-19 as a STING disorder with delayed over-secretion of interferon-beta.|pdf=|usr=}}
{{tp|p=32393438|t=2020. Intelligent classification of platelet aggregates by agonist type.|pdf=|usr=}}
{{tp|p=32529906|t=2020. Serological differentiation between COVID-19 and SARS infections.|pdf=|usr=}}
{{tp|p=32529952|t=2020. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists.|pdf=|usr=}}
{{tp|p=32525765|t=2020. Genetic cluster analysis of SARS-CoV-2 and the identification of those responsible for the major outbreaks in various countries.|pdf=|usr=}}
{{tp|p=32515685|t=2020. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19.|pdf=|usr=}}
{{tp|p=32515684|t=2020. Patterns of IgG and IgM antibody response in COVID-19 patients.|pdf=|usr=}}
{{tp|p=32380903|t=2020. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32533508|t=2020. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19.|pdf=|usr=}}
{{tp|p=32419876|t=2020. Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for predictive, preventive, and personalized medical approach.|pdf=|usr=}}
{{tp|p=32444797|t=2020. BBMRI-ERIC's contributions to research and knowledge exchange on COVID-19.|pdf=|usr=}}
{{tp|p=32415272|t=2020. Connecting data, tools and people across Europe: ELIXIR's response to the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=32404885|t=2020. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic.|pdf=|usr=}}
{{tp|p=32376989|t=2020. The VODAN IN: support of a FAIR-based infrastructure for COVID-19.|pdf=|usr=}}
{{tp|p=32335973|t=2020. Of mice and men: COVID-19 challenges translational neuroscience.|pdf=|usr=}}
{{tp|p=32444400|t=2020. COVID-19 and the nicotinic cholinergic system.|pdf=|usr=}}
{{tp|p=32398299|t=2020. To compare the incomparable: COVID-19 pneumonia and high altitude disease.|pdf=|usr=}}
{{tp|p=32432790|t=2020. Editorial - COVID-19 and the microbiota: new kids on the block.|pdf=|usr=}}
{{tp|p=32432787|t=2020. SARS-CoV-2 identification in lungs, heart and kidney specimens by transmission and scanning electron microscopy.|pdf=|usr=}}
{{tp|p=32524957|t=2020. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020.|pdf=|usr=}}
{{tp|p=32524946|t=2020. Genetic structure of SARS-CoV-2 reflects clonal superspreading and multiple independent introduction events, North-Rhine Westphalia, Germany, February and March 2020.|pdf=|usr=}}
{{tp|p=32474064|t=2020. A novel cell-based assay for dynamically detecting neutrophil extracellular traps-induced lung epithelial injuries.|pdf=|usr=}}
{{tp|p=32454103|t=2020. Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection.|pdf=|usr=}}
{{tp|p=32489244|t=2020. Microthrombotic Complications of COVID-19 Are Likely Due to Embolism of Circulating Endothelial Derived Ultralarge Von Willebrand Factor (eULVWF) Decorated-Platelet Strings.|pdf=|usr=}}
{{tp|p=32399755|t=2020. A technical report from the Italian SARS-CoV-2 outbreak. Postmortem sampling and autopsy investigation in cases of suspected or probable COVID-19.|pdf=|usr=}}
{{tp|p=32425955|t=2020. Potential SARS-CoV-2 Preimmune IgM Epitopes.|pdf=|usr=}}
{{tp|p=32425950|t=2020. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=32391299|t=2020. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children.|pdf=|usr=}}
{{tp|p=32442562|t=2020. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization.|pdf=|usr=}}
{{tp|p=32413354|t=2020. Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease.|pdf=|usr=}}
{{tp|p=32437749|t=2020. Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2.|pdf=|usr=}}
{{tp|p=32445924|t=2020. Overwhelming mutations or SNPs of SARS-CoV-2: A point of caution.|pdf=|usr=}}
{{tp|p=32510005|t=2020. COVID-19 target: A specific target for novel coronavirus detection.|pdf=|usr=}}
{{tp|p=32526937|t=2020. Analysis of the Hosts and Transmission Paths of SARS-CoV-2 in the COVID-19 Outbreak.|pdf=|usr=}}
{{tp|p=32520981|t=2020. ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32504168|t=2020. Impact of glycoscience in fighting Covid-19.|pdf=|usr=}}
{{tp|p=32522249|t=2020. Genomics of COVID-19: molecular mechanisms going from susceptibility to severity of the disease.|pdf=|usr=}}
{{tp|p=32437706|t=2020. Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report.|pdf=|usr=}}
{{tp|p=32483525|t=2020. A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm).|pdf=|usr=}}
{{tp|p=32433946|t=2020. Herd Immunity: Understanding COVID-19.|pdf=|usr=}}
{{tp|p=32392464|t=2020. SARS-CoV-2: Combating Coronavirus Emergence.|pdf=|usr=}}
{{tp|p=32497522|t=2020. Respiratory Virus Infections: Understanding COVID-19.|pdf=|usr=}}
{{tp|p=32413330|t=2020. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.|pdf=|usr=}}
{{tp|p=32534867|t=2020. Sequence homology between human PARP14 and the SARS-CoV-2 ADP ribose 1'-phosphatase.|pdf=|usr=}}
{{tp|p=32524333|t=2020. COVID 19: a clue from innate immunity.|pdf=|usr=}}
{{tp|p=32473952|t=2020. SARS-CoV-2: The viral shedding vs infectivity dilemma.|pdf=|usr=}}
{{tp|p=32509257|t=2020. SARS-CoV-2, "common cold" coronaviruses' cross-reactivity and "herd immunity": The razor of Ockham (1285-1347)?|pdf=|usr=}}
{{tp|p=32474891|t=2020. COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia.|pdf=|usr=}}
{{tp|p=32473977|t=2020. Unfolding SARS-CoV-2 viral genome to understand its gene expression regulation.|pdf=|usr=}}
{{tp|p=32473976|t=2020. SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective.|pdf=|usr=}}
{{tp|p=32473352|t=2020. Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.|pdf=|usr=}}
{{tp|p=32450246|t=2020. Molecular epidemiology of SARS-CoV-2 in Faisalabad, Pakistan: A real-world clinical experience.|pdf=|usr=}}
{{tp|p=32405281|t=2020. Sars-CoV-2 and black population: ACE2 as shield or blade?|pdf=|usr=}}
{{tp|p=32502733|t=2020. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach.|pdf=|usr=}}
{{tp|p=32524515|t=2020. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals.|pdf=|usr=}}
{{tp|p=32532942|t=2020. MERS-CoV and SARS-CoV infections in animals: a systematic review and meta-analysis of prevalence studies.|pdf=|usr=}}
{{tp|p=32529477|t=2020. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".|pdf=|usr=}}
{{tp|p=32501423|t=2020. Developing an ultra-efficient microsatellite discoverer to find structural differences between SARS-CoV-1 and Covid-19.|pdf=|usr=}}
{{tp|p=32531713|t=2020. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.|pdf=|usr=}}
{{tp|p=32437920|t=2020. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line.|pdf=|usr=}}
{{tp|p=32534186|t=2020. Procalcitonin levels in COVID-19 patients.|pdf=|usr=}}
{{tp|p=32485251|t=2020. A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32516845|t=2020. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19.|pdf=|usr=}}
{{tp|p=32530491|t=2020. Presepsin as a predictive biomarker of severity in COVID-19: A case series.|pdf=|usr=}}
{{tp|p=32519791|t=2020. Hypoalbuminaemia in COVID-19 infection: A predictor of severity or a potential therapeutic target?|pdf=|usr=}}
{{tp|p=32519786|t=2020. Pulmonary Capillary Leak Syndrome following COVID-19 Virus Infection.|pdf=|usr=}}
{{tp|p=32519768|t=2020. Hyperpyrexia in COVID-19 patients.|pdf=|usr=}}
{{tp|p=32526083|t=2020. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19.|pdf=|usr=}}
{{tp|p=32530583|t=2020. Neuropathological Features of Covid-19.|pdf=|usr=}}
{{tp|p=32534467|t=2020. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.|pdf=|usr=}}
{{tp|p=32515386|t=2020. Glucovigilance in COVID-19.|pdf=|usr=}}
{{tp|p=32515374|t=2020. The Microbiology of Coronaviruses.|pdf=|usr=}}
{{tp|p=31896597|t=2020. Host AAA+ ATPase TER94 Plays Critical Roles in Building the Baculovirus Viral Replication Factory and Virion Morphogenesis.|pdf=|usr=}}
{{tp|p=32518411|t=2020. Genomic search for COVID-19 severity clues.|pdf=|usr=}}
{{tp|p=32514174|t=2020. A single-cell atlas of the peripheral immune response in patients with severe COVID-19.|pdf=|usr=}}
{{tp|p=32528156|t=2020. Ten recommendations for supporting open pathogen genomic analysis in public health.|pdf=|usr=}}
{{tp|p=32528149|t=2020. Kawasaki disease in a COVID-19-struck region.|pdf=|usr=}}
{{tp|p=32427517|t=2020. COVID-19 Pandemic: Hopes from Proteomics and Multiomics Research.|pdf=|usr=}}
{{tp|p=32533838|t=2020. The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review.|pdf=|usr=}}
{{tp|p=32527802|t=2020. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.|pdf=|usr=}}
{{tp|p=32467368|t=2020. Doctors race to understand inflammatory condition in kids.|pdf=|usr=}}
{{tp|p=32467367|t=2020. Scientists put survivors' blood plasma to the test.|pdf=|usr=}}
{{tp|p=32439770|t=2020. T cells found in coronavirus patients 'bode well' for long-term immunity.|pdf=|usr=}}
{{tp|p=32527928|t=2020. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection.|pdf=|usr=}}
{{tp|p=32527925|t=2020. Type III interferons disrupt the lung epithelial barrier upon viral recognition.|pdf=|usr=}}
{{tp|p=32526773|t=2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.|pdf=|usr=}}
{{tp|p=32513613|t=2020. COVID-19 and the ABO blood group connection.|pdf=|usr=}}

PMC7256503 113. Type 3 hypersensitivity in COVID-19 vasculitis.

Clin Immunol 2020; 217 (ä): 108487

*32479986*
                       32479986

PMC7256549 114. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.

Clin Immunol 2020; 217 (ä): 108486

*32479985*
                       32479985

PMC7253967 115. Racial disparity in Covid-19 mortality rates - A plausible explanation.

Clin Immunol 2020; 217 (ä): 108481

*32473354*
                       32473354

PMC7260446 116. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.

Clin Rheumatol 2020; 39 (7): 2085-2094

*32474885*
                       32474885

PMC7251560 117. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia.

Clin Rheumatol 2020; 39 (7): 2095-2097

*32462425*
                       32462425

PMC7211507 118. Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence.

Clin Transl Immunology 2020; 9 (5): e1128

*32399213*
                       32399213

PMC7209766 119. COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review.

Crit Care 2020; 24 (1): 205

*32384917*
                       32384917

PMC7250249 120. COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.

Crit Care 2020; 24 (1): 263

*32456696*
                       32456696

PMC7249975 121. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.

Crit Care 2020; 24 (1): 255

*32456658*
                       32456658

PMC7228671 122. COVID-19: room for treating T cell exhaustion?

Crit Care 2020; 24 (1): 229

*32414395*
                       32414395

PMC7224163 123. Age and sex differences in soluble ACE2 may give insights for COVID-19.

Crit Care 2020; 24 (1): 221

*32410690*
                       32410690

PMC7280775 124. Systemic hypoferremia and severity of hypoxemic respiratory failure in COVID-19.

Crit Care 2020; 24 (1): 320

*32517773*
                       32517773

PMC7268578 125. Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines.

Cureus 2020; 12 (6): e8399

*32499988*
                       32499988

PMC7211627 126. A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein.

Curr Biol 2020; 30 (11): 2196-2203.e3

*32416074*
                       32416074

PMC7241386 127. Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions.

Cytokine 2020; 133 (ä): 155143

*32460144*
                       32460144

PMC7272164 128. Letter to the Editor on "Bonafe M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev".

Cytokine Growth Factor Rev 2020; ä (ä): ä

*32522400*
                       32522400

PMC7265853 129. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.

Cytokine Growth Factor Rev 2020; ä (ä): ä

*32513566*
                       32513566

PMC7237916 130. IL-6: Relevance for immunopathology of SARS-CoV-2.

Cytokine Growth Factor Rev 2020; 53 (ä): 13-24

*32475759*
                       32475759

PMC7211650 131. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.

Cytokine Growth Factor Rev 2020; 53 (ä): 25-32

*32446778*
                       32446778

PMC7252014 132. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes.

Cytokine Growth Factor Rev 2020; 53 (ä): 33-37

*32389499*
                       32389499

PMC7224649 133. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.

Cytokine X 2020; ä (ä): 100029

*32421092*
                       32421092

PMC7214326 134. Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.

Diabetes Metab Syndr 2020; 14 (4): 713-714

*32470851*
                       32470851

PMC7215143 135. Mechanism of inflammatory response in associated comorbidities in COVID-19.

Diabetes Metab Syndr 2020; 14 (4): 597-600

*32417709*
                       32417709

PMC7280780 136. Histopathology of COVID-19 pneumonia in two non-oncological, non-hospitalised cases as a reliable diagnostic benchmark.

Diagn Pathol 2020; 15 (1): 73

*32517769*
                       32517769

PMC7273095 137. Androgen sensitivity gateway to COVID-19 disease severity.

Drug Dev Res 2020; ä (ä): ä

*32412125*
                       32412125

PMC7244443 138. COVID-19 as a STING disorder with delayed over-secretion of interferon-beta.

EBioMedicine 2020; 56 (ä): 102801

*32454408*
                       32454408

PMC7217700 139. Intelligent classification of platelet aggregates by agonist type.

Elife 2020; 9 (ä): ä

*32393438*
                       32393438

140. Serological differentiation between COVID-19 and SARS infections.

Emerg Microbes Infect 2020; ä (ä): 1-23

*32529906*
                       32529906

141. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists.

Emerg Microbes Infect 2020; 9 (1): 1418-1428

*32529952*
                       32529952

142. Genetic cluster analysis of SARS-CoV-2 and the identification of those responsible for the major outbreaks in various countries.

Emerg Microbes Infect 2020; 9 (1): 1287-1299

*32525765*
                       32525765

143. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19.

Emerg Microbes Infect 2020; 9 (1): 1254-1258

*32515685*
                       32515685

144. Patterns of IgG and IgM antibody response in COVID-19 patients.

Emerg Microbes Infect 2020; 9 (1): 1269-1274

*32515684*
                       32515684

PMC7241448 145. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.

Emerg Microbes Infect 2020; 9 (1): 900-902

*32380903*
                       32380903

PMC7292572 146. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19.

Endocrine 2020; 68 (3): 475-478

*32533508*
                       32533508

PMC7224348 147. Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for predictive, preventive, and personalized medical approach.

EPMA J 2020; ä (ä): 1-7

*32419876*
                       32419876

PMC7242892 148. BBMRI-ERIC's contributions to research and knowledge exchange on COVID-19.

Eur J Hum Genet 2020; 28 (6): 728-731

*32444797*
                       32444797

PMC7225634 149. Connecting data, tools and people across Europe: ELIXIR's response to the COVID-19 pandemic.

Eur J Hum Genet 2020; 28 (6): 719-723

*32415272*
                       32415272

PMC7220587 150. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic.

Eur J Hum Genet 2020; 28 (6): 715-718

*32404885*
                       32404885

PMC7201909 151. The VODAN IN: support of a FAIR-based infrastructure for COVID-19.

Eur J Hum Genet 2020; 28 (6): 724-727

*32376989*
                       32376989

PMC7267512 152. Of mice and men: COVID-19 challenges translational neuroscience.

Eur J Neurol 2020; ä (ä): ä

*32335973*
                       32335973

PMC7248130 153. COVID-19 and the nicotinic cholinergic system.

Eur Respir J 2020; ä (ä): ä

*32444400*
                       32444400

154. To compare the incomparable: COVID-19 pneumonia and high altitude disease.

Eur Respir J 2020; ä (ä): ä

*32398299*
                       32398299

155. Editorial - COVID-19 and the microbiota: new kids on the block.

Eur Rev Med Pharmacol Sci 2020; 24 (9): 5189-5191

*32432790*
                       32432790

156. SARS-CoV-2 identification in lungs, heart and kidney specimens by transmission and scanning electron microscopy.

Eur Rev Med Pharmacol Sci 2020; 24 (9): 5186-5188

*32432787*
                       32432787

157. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020.

Euro Surveill 2020; 25 (22): ä

*32524957*
                       32524957

158. Genetic structure of SARS-CoV-2 reflects clonal superspreading and multiple independent introduction events, North-Rhine Westphalia, Germany, February and March 2020.

Euro Surveill 2020; 25 (22): ä

*32524946*
                       32524946

PMC7256615 159. A novel cell-based assay for dynamically detecting neutrophil extracellular traps-induced lung epithelial injuries.

Exp Cell Res 2020; ä (ä): 112101

*32474064*
                       32474064

PMC7245307 160. Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection.

Exp Mol Pathol 2020; 115 (ä): 104474

*32454103*
                       32454103

PMC7241602 161. Microthrombotic Complications of COVID-19 Are Likely Due to Embolism of Circulating Endothelial Derived Ultralarge Von Willebrand Factor (eULVWF) Decorated-Platelet Strings.

Fed Pract 2020; 37 (6): e1-e2

*32489244*
                       32489244

PMC7216855 162. A technical report from the Italian SARS-CoV-2 outbreak. Postmortem sampling and autopsy investigation in cases of suspected or probable COVID-19.

Forensic Sci Med Pathol 2020; ä (ä): ä

*32399755*
                       32399755

PMC7203467 163. Potential SARS-CoV-2 Preimmune IgM Epitopes.

Front Immunol 2020; 11 (ä): 932

*32425955*
                       32425955

PMC7205903 164. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).

Front Immunol 2020; 11 (ä): 827

*32425950*
                       32425950

PMC7192005 165. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children.

Front Pediatr 2020; 8 (ä): 206

*32391299*
                       32391299

PMC7237927 166. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization.

Gastroenterology 2020; ä (ä): ä

*32442562*
                       32442562

PMC7217073 167. Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease.

Gastroenterology 2020; ä (ä): ä

*32413354*
                       32413354

PMC7211585 168. Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2.

Gastroenterology 2020; ä (ä): ä

*32437749*
                       32437749

PMC7239005 169. Overwhelming mutations or SNPs of SARS-CoV-2: A point of caution.

Gene 2020; 752 (ä): 144792

*32445924*
                       32445924

PMC7261075 170. COVID-19 target: A specific target for novel coronavirus detection.

Gene Rep 2020; 20 (ä): 100740

*32510005*
                       32510005

171. Analysis of the Hosts and Transmission Paths of SARS-CoV-2 in the COVID-19 Outbreak.

Genes (Basel) 2020; 11 (6): ä

*32526937*
                       32526937

PMC7278419 172. ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2.

Genet Mol Biol 2020; 43 (2): e20200104

*32520981*
                       32520981

PMC7273117 173. Impact of glycoscience in fighting Covid-19.

Glycoconj J 2020; ä (ä): ä

*32504168*
                       32504168

PMC7283035 174. Genomics of COVID-19: molecular mechanisms going from susceptibility to severity of the disease.

Hum Genomics 2020; 14 (1): 22

*32522249*
                       32522249

PMC7211665 175. Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report.

Hum Pathol 2020; ä (ä): ä

*32437706*
                       32437706

PMC7236721 176. A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm).

IDCases 2020; 21 (ä): e00829

*32483525*
                       32483525

PMC7236739 177. Herd Immunity: Understanding COVID-19.

Immunity 2020; 52 (5): 737-741

*32433946*
                       32433946

PMC7207110 178. SARS-CoV-2: Combating Coronavirus Emergence.

Immunity 2020; 52 (5): 734-736

*32392464*
                       32392464

PMC7237932 179. Respiratory Virus Infections: Understanding COVID-19.

Immunity 2020; 52 (6): 905-909

*32497522*
                       32497522

PMC7196424 180. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.

Immunity 2020; 52 (6): 971-977.e3

*32413330*
                       32413330

PMC7289111 181. Sequence homology between human PARP14 and the SARS-CoV-2 ADP ribose 1'-phosphatase.

Immunol Lett 2020; ä (ä): ä

*32534867*
                       32534867

PMC7286633 182. COVID 19: a clue from innate immunity.

Immunol Res 2020; ä (ä): ä

*32524333*
                       32524333

PMC7237903 183. SARS-CoV-2: The viral shedding vs infectivity dilemma.

Infect Dis Health 2020; ä (ä): ä

*32473952*
                       32473952

PMC7267809 184. SARS-CoV-2, "common cold" coronaviruses' cross-reactivity and "herd immunity": The razor of Ockham (1285-1347)?

Infect Dis Rep 2020; 12 (2): 8647

*32509257*
                       32509257

PMC7260454 185. COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia.

Infect Dis Ther 2020; ä (ä): ä

*32474891*
                       32474891

PMC7256514 186. Unfolding SARS-CoV-2 viral genome to understand its gene expression regulation.

Infect Genet Evol 2020; 84 (ä): 104386

*32473977*
                       32473977

PMC7256558 187. SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective.

Infect Genet Evol 2020; 84 (ä): 104384

*32473976*
                       32473976

PMC7251353 188. Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.

Infect Genet Evol 2020; 84 (ä): 104382

*32473352*
                       32473352

PMC7242943 189. Molecular epidemiology of SARS-CoV-2 in Faisalabad, Pakistan: A real-world clinical experience.

Infect Genet Evol 2020; 84 (ä): 104374

*32450246*
                       32450246

PMC7219352 190. Sars-CoV-2 and black population: ACE2 as shield or blade?

Infect Genet Evol 2020; 84 (ä): 104361

*32405281*
                       32405281

PMC7266584 191. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach.

Infect Genet Evol 2020; 84 (ä): 104389

*32502733*
                       32502733

PMC7286418 192. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals.

Infection 2020; ä (ä): ä

*32524515*
                       32524515

193. MERS-CoV and SARS-CoV infections in animals: a systematic review and meta-analysis of prevalence studies.

Infez Med 2020; 28 (suppl 1): 71-83

*32532942*
                       32532942

PMC7289226 194. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".

Inflamm Res 2020; ä (ä): ä

*32529477*
                       32529477

PMC7241407 195. Developing an ultra-efficient microsatellite discoverer to find structural differences between SARS-CoV-1 and Covid-19.

Inform Med Unlocked 2020; 19 (ä): 100356

*32501423*
                       32501423

PMC7275184 196. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.

Int Immunopharmacol 2020; 85 (ä): 106683

*32531713*
                       32531713

PMC7211594 197. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line.

Int J Antimicrob Agents 2020; ä (ä): 106017

*32437920*
                       32437920

PMC7286278 198. Procalcitonin levels in COVID-19 patients.

Int J Antimicrob Agents 2020; ä (ä): 106051

*32534186*
                       32534186

PMC7260514 199. A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2.

Int J Biol Macromol 2020; 160 (ä): 736-740

*32485251*
                       32485251

PMC7301027 200. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19.

J Med Virol 2020; ä (ä): ä

*32516845*
                       32516845

PMC7307131 201. Presepsin as a predictive biomarker of severity in COVID-19: A case series.

J Med Virol 2020; ä (ä): ä

*32530491*
                       32530491

PMC7307076 202. Hypoalbuminaemia in COVID-19 infection: A predictor of severity or a potential therapeutic target?

J Med Virol 2020; ä (ä): ä

*32519791*
                       32519791

PMC7300440 203. Pulmonary Capillary Leak Syndrome following COVID-19 Virus Infection.

J Med Virol 2020; ä (ä): ä

*32519786*
                       32519786

PMC7300797 204. Hyperpyrexia in COVID-19 patients.

J Med Virol 2020; ä (ä): ä

*32519768*
                       32519768

PMC7307119 205. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19.

Liver Int 2020; ä (ä): ä

*32526083*
                       32526083

PMC7304421 206. Neuropathological Features of Covid-19.

N Engl J Med 2020; ä (ä): ä

*32530583*
                       32530583

207. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.

J Leukoc Biol 2020; ä (ä): ä

*32534467*
                       32534467

208. Glucovigilance in COVID-19.

J Pak Med Assoc 2020; 70(Suppl 3) (5): S80-S82

*32515386*
                       32515386

209. The Microbiology of Coronaviruses.

J Pak Med Assoc 2020; 70(Suppl 3) (5): S44-S47

*32515374*
                       32515374

PMC7158741 210. Host AAA+ ATPase TER94 Plays Critical Roles in Building the Baculovirus Viral Replication Factory and Virion Morphogenesis.

J Virol 2020; 94 (6): ä

*31896597*
                       31896597

211. Genomic search for COVID-19 severity clues.

Nat Biotechnol 2020; 38 (6): 657

*32518411*
                       32518411

212. A single-cell atlas of the peripheral immune response in patients with severe COVID-19.

Nat Med 2020; ä (ä): ä

*32514174*
                       32514174

213. Ten recommendations for supporting open pathogen genomic analysis in public health.

Nat Med 2020; 26 (6): 832-841

*32528156*
                       32528156

214. Kawasaki disease in a COVID-19-struck region.

Nat Med 2020; 26 (6): 822

*32528149*
                       32528149

215. COVID-19 Pandemic: Hopes from Proteomics and Multiomics Research.

OMICS 2020; ä (ä): ä

*32427517*
                       32427517

216. The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review.

Pathog Dis 2020; 78 (3): ä

*32533838*
                       32533838

217. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.

Sci Immunol 2020; 5 (48): ä

*32527802*
                       32527802

218. Doctors race to understand inflammatory condition in kids.

Science 2020; 368 (6494): 923-924

*32467368*
                       32467368

219. Scientists put survivors' blood plasma to the test.

Science 2020; 368 (6494): 922-923

*32467367*
                       32467367

220. T cells found in coronavirus patients 'bode well' for long-term immunity.

Science 2020; 368 (6493): 809-810

*32439770*
                       32439770

221. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection.

Science 2020; ä (ä): ä

*32527928*
                       32527928

222. Type III interferons disrupt the lung epithelial barrier upon viral recognition.

Science 2020; ä (ä): ä

*32527925*
                       32527925

223. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.

Semin Thromb Hemost 2020; ä (ä): ä

*32526773*
                       32526773

224. COVID-19 and the ABO blood group connection.

Transfus Apher Sci 2020; ä (ä): 102838

*32513613*
                       32513613


{{tp|p=32449057|t=2020. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology.|pdf=|usr=}}
{{tp|p=32220035|t=2020. SARS-CoV-2: What do we know so far?|pdf=|usr=}}
{{tp|p=32534452|t=2020. From causes of aging to death from COVID-19.|pdf=|usr=}}
{{tp|p=32339157|t=2020. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.|pdf=|usr=}}
{{tp|p=32489708|t=2020. Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=32489698|t=2020. COVID-19 Virulence in Aged Patients Might Be Impacted by the Host Cellular MicroRNAs Abundance/Profile.|pdf=|usr=}}
{{tp|p=32401346|t=2020. SARS-CoV-2 immunogenicity at the crossroads.|pdf=|usr=}}
{{tp|p=32396996|t=2020. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.|pdf=|usr=}}
{{tp|p=32053148|t=2020. Three Emerging Coronaviruses in Two Decades.|pdf=|usr=}}
{{tp|p=32475764|t=2020. An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients.|pdf=|usr=}}
{{tp|p=32513452|t=2020. Abdominal pain in a patient with COVID-19 infection: A case of multiple thromboemboli.|pdf=|usr=}}
{{tp|p=32471782|t=2020. Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department.|pdf=|usr=}}
{{tp|p=32471783|t=2020. Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.|pdf=|usr=}}
{{tp|p=32425320|t=2020. Nitrous oxide inhalant abuse and massive pulmonary embolism in COVID-19.|pdf=|usr=}}
{{tp|p=32532619|t=2020. Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C).|pdf=|usr=}}
{{tp|p=32405074|t=2020. Visualization of SARS-CoV-2 virus invading the human placenta using electron microscopy.|pdf=|usr=}}
{{tp|p=32533928|t=2020. Letter-to-the-Editor: Alternative Interpretation to the Findings Reported in Visualization of SARS-CoV-2 Virus Invading the Human Placenta Using Electron Microscopy.|pdf=|usr=}}
{{tp|p=32391518|t=2020. Detection of SARS-COV-2 in Placental and Fetal Membrane Samples.|pdf=|usr=}}
{{tp|p=32427221|t=2020. Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth.|pdf=|usr=}}
{{tp|p=32471774|t=2020. SARS-CoV-2: Naso-bronchial cytological correlations.|pdf=|usr=}}
{{tp|p=32516444|t=2020. Immunological environment shifts during pregnancy may affect the risk of developing severe complications in COVID-19 patients.|pdf=|usr=}}
{{tp|p=32439309|t=2020. Revision narrativa sobre la respuesta inmunitaria frente a coronavirus: descripcion general, aplicabilidad para SARS-COV-2 e implicaciones terapeuticas.|pdf=|usr=}}
{{tp|p=32505756|t=2020. Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.|pdf=|usr=}}
{{tp|p=32505755|t=2020. Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.|pdf=|usr=}}
{{tp|p=32526061|t=2020. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.|pdf=|usr=}}
{{tp|p=32502135|t=2020. Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients.|pdf=|usr=}}
{{tp|p=32458111|t=2020. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.|pdf=|usr=}}
{{tp|p=32414383|t=2020. Plasma CRP level is positively associated with the severity of COVID-19.|pdf=|usr=}}
{{tp|p=32387855|t=2020. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.|pdf=|usr=}}
{{tp|p=32462329|t=2020. Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19.|pdf=|usr=}}
{{tp|p=32500224|t=2020. Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy-a case report.|pdf=|usr=}}
{{tp|p=32495027|t=2020. Hematological findings in coronavirus disease 2019: indications of progression of disease.|pdf=|usr=}}
{{tp|p=32529285|t=2020. SARS-CoV-2 infection in children with febrile neutropenia.|pdf=|usr=}}
{{tp|p=32529284|t=2020. Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=32382776|t=2020. Signals of Th2 immune response from COVID-19 patients requiring intensive care.|pdf=|usr=}}
{{tp|p=32436075|t=2020. Microvascular alterations in patients with SARS-COV-2 severe pneumonia.|pdf=|usr=}}
{{tp|p=32488505|t=2020. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children.|pdf=|usr=}}
{{tp|p=32422085|t=2020. Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report.|pdf=|usr=}}
{{tp|p=32527868|t=2020. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort.|pdf=|usr=}}
{{tp|p=32395525|t=2020. A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=32405117|t=2020. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32532524|t=2020. SARS-CoV-2-A Tough Opponent for the Immune System.|pdf=|usr=}}
{{tp|p=32493627|t=2020. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2.|pdf=|usr=}}
{{tp|p=32471702|t=2020. Defective Anti-oxidant System: An Aggravating Factor for COVID-19 Patients Outcome?|pdf=|usr=}}
{{tp|p=32471703|t=2020. Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.|pdf=|usr=}}
{{tp|p=32419712|t=2020. COVID-19 and Dysfunctional Endothelium: The Mexican Scenario.|pdf=|usr=}}
{{tp|p=32535095|t=2020. Molecular mimicry may explain multi-organ damage in COVID-19.|pdf=|usr=}}
{{tp|p=32535093|t=2020. Covid-19 and autoimmunity.|pdf=|usr=}}
{{tp|p=32410735|t=2020. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.|pdf=|usr=}}
{{tp|p=32485205|t=2020. The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway.|pdf=|usr=}}
{{tp|p=32479856|t=2020. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention.|pdf=|usr=}}
{{tp|p=32480226|t=2020. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.|pdf=|usr=}}
{{tp|p=32425294|t=2020. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.|pdf=|usr=}}
{{tp|p=32407552|t=2020. Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient.|pdf=|usr=}}
{{tp|p=32529634|t=2020. Haemophagocytosis in bone marrow aspirates in patients with COVID-19.|pdf=|usr=}}
{{tp|p=32526046|t=2020. Secondary HLH is uncommon in severe COVID-19.|pdf=|usr=}}
{{tp|p=32446945|t=2020. Do matrix metalloproteases mediate the SARS-CoV-2-related damage to the central nervous system?|pdf=|usr=}}
{{tp|p=32454136|t=2020. The role of IgA in COVID-19.|pdf=|usr=}}
{{tp|p=32512702|t=2020. COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination.|pdf=|usr=}}
{{tp|p=32479746|t=2020. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.|pdf=|usr=}}
{{tp|p=32492406|t=2020. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.|pdf=|usr=}}
{{tp|p=32416070|t=2020. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.|pdf=|usr=}}
{{tp|p=32413319|t=2020. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.|pdf=|usr=}}
{{tp|p=32526206|t=2020. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.|pdf=|usr=}}
{{tp|p=32526208|t=2020. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.|pdf=|usr=}}
{{tp|p=32516571|t=2020. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.|pdf=|usr=}}
{{tp|p=32473127|t=2020. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.|pdf=|usr=}}
{{tp|p=32425270|t=2020. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.|pdf=|usr=}}
{{tp|p=32405102|t=2020. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=32514047|t=2020. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19).|pdf=|usr=}}
{{tp|p=32513989|t=2020. The inhibition of IL-2/IL-2R gives rise to CD8(+) T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=32499922|t=2020. ACE2 expression and sex disparity in COVID-19.|pdf=|usr=}}
{{tp|p=32485164|t=2020. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis.|pdf=|usr=}}
{{tp|p=32464098|t=2020. The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?|pdf=|usr=}}
{{tp|p=32415260|t=2020. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.|pdf=|usr=}}
{{tp|p=32398804|t=2020. Is aberrant CD8+ T cell activation by hypertension associated with cardiac injury in severe cases of COVID-19?|pdf=|usr=}}
{{tp|p=32426212|t=2020. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.|pdf=|usr=}}
{{tp|p=32531208|t=2020. Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32458383|t=2020. On barring the vascular gateway against severe COVID-19 disease.|pdf=|usr=}}
{{tp|p=32500379|t=2020. COVID-19 and heme oxygenase: novel insight into the disease and potential therapies.|pdf=|usr=}}
{{tp|p=32454047|t=2020. An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19.|pdf=|usr=}}
{{tp|p=32417210|t=2020. The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?|pdf=|usr=}}
{{tp|p=32405080|t=2020. Decreased T cell populations contribute to the increased severity of COVID-19.|pdf=|usr=}}
{{tp|p=32531257|t=2020. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients.|pdf=|usr=}}
{{tp|p=32531256|t=2020. Cytokine Storm Induced by SARS-CoV-2.|pdf=|usr=}}
{{tp|p=32461193|t=2020. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.|pdf=|usr=}}
{{tp|p=32526273|t=2020. A plea for the pathogenic role of immune complexes in severe Covid-19.|pdf=|usr=}}
{{tp|p=32407466|t=2020. An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19.|pdf=|usr=}}
{{tp|p=32454188|t=2020. Correlation between viral RNA shedding and serum antibodies in individuals with coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=32447048|t=2020. SARS-CoV-2 persisted in lung tissue despite disappearance in other clinical samples.|pdf=|usr=}}
{{tp|p=32526483|t=2020. COVID 19 and brain crosstalks.|pdf=|usr=}}
{{tp|p=32525600|t=2020. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.|pdf=|usr=}}
{{tp|p=32535877|t=2020. Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19).|pdf=|usr=}}
{{tp|p=32533690|t=2020. Placental Pathology in COVID-19.|pdf=|usr=}}
{{tp|p=32432897|t=2020. Reply: COVID-19 Lung Injury and "Typical" ARDS: The Danger of Presumed Equivalency.|pdf=|usr=}}
{{tp|p=32432896|t=2020. Respiratory Mechanics and Gas Exchange in COVID-19 Associated Respiratory Failure.|pdf=|usr=}}
{{tp|p=32432895|t=2020. COVID-19 Lung Injury and "Typical" ARDS: The Danger of Presumed Equivalency.|pdf=|usr=}}
{{tp|p=32434816|t=2020. Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?|pdf=|usr=}}
{{tp|p=32524832|t=2020. Is Albumin Predictor of Mortality in COVID-19?|pdf=|usr=}}
{{tp|p=32531085|t=2020. C1-INH and the contact system in COVID-19.|pdf=|usr=}}
{{tp|p=32533986|t=2020. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=32526272|t=2020. Antibody-dependent enhancement and COVID-19: Moving toward acquittal.|pdf=|usr=}}
{{tp|p=32533824|t=2020. Tuberculosis and type 2 Diabetes Mellitus: an inflammatory danger signal in the time of COVID-19.|pdf=|usr=}}
{{tp|p=32517505|t=2020. C3 polymorphisms represent an important immunological confounder on the spread and outcome of COVID-19.|pdf=|usr=}}
{{tp|p=32518941|t=2020. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics.|pdf=|usr=}}
{{tp|p=32522666|t=2020. How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?|pdf=|usr=}}
{{tp|p=32526370|t=2020. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?|pdf=|usr=}}
{{tp|p=32525565|t=2020. Elevated expression of ACE2 in tumor-adjacent normal tissues of cancer patients.|pdf=|usr=}}
{{tp|p=32425712|t=2020. Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.|pdf=|usr=}}
{{tp|p=32535977|t=2020. Introductory histopathologic findings may shed light on COVID19 pediatric hyperinflammatory shock syndrome.|pdf=|usr=}}
{{tp|p=32513850|t=2020. Early Insights into Immune Responses during COVID-19.|pdf=|usr=}}
{{tp|p=32526012|t=2020. ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19.|pdf=|usr=}}

PMC7245994 225. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology.

Acta Neuropathol 2020; 140 (1): 1-6

*32449057*
                       32449057

PMC7228362 226. SARS-CoV-2: What do we know so far?

Acta Physiol (Oxf) 2020; 229 (2): e13470

*32220035*
                       32220035

227. From causes of aging to death from COVID-19.

Aging (Albany NY) 2020; 12 (11): 10004-10021

*32534452*
                       32534452

PMC7202533 228. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.

Aging (Albany NY) 2020; 12 (8): 6518-6535

*32339157*
                       32339157

PMC7220292 229. Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19).

Aging Dis 2020; 11 (3): 642-648

*32489708*
                       32489708

PMC7220294 230. COVID-19 Virulence in Aged Patients Might Be Impacted by the Host Cellular MicroRNAs Abundance/Profile.

Aging Dis 2020; 11 (3): 509-522

*32489698*
                       32489698

PMC7272904 231. SARS-CoV-2 immunogenicity at the crossroads.

Allergy 2020; ä (ä): ä

*32401346*
                       32401346

PMC7272948 232. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.

Allergy 2020; ä (ä): ä

*32396996*
                       32396996

PMC7109697 233. Three Emerging Coronaviruses in Two Decades.

Am J Clin Pathol 2020; 153 (4): 420-421

*32053148*
                       32053148

PMC7251355 234. An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients.

Am J Emerg Med 2020; ä (ä): ä

*32475764*
                       32475764

PMC7248631 235. Abdominal pain in a patient with COVID-19 infection: A case of multiple thromboemboli.

Am J Emerg Med 2020; ä (ä): ä

*32513452*
                       32513452

PMC7255141 236. Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department.

Am J Emerg Med 2020; ä (ä): ä

*32471782*
                       32471782

PMC7243756 237. Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.

Am J Emerg Med 2020; ä (ä): ä

*32471783*
                       32471783

PMC7229475 238. Nitrous oxide inhalant abuse and massive pulmonary embolism in COVID-19.

Am J Emerg Med 2020; ä (ä): ä

*32425320*
                       32425320

PMC7274960 239. Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C).

Am J Emerg Med 2020; ä (ä): ä

*32532619*
                       32532619

PMC7219376 240. Visualization of SARS-CoV-2 virus invading the human placenta using electron microscopy.

Am J Obstet Gynecol 2020; ä (ä): ä

*32405074*
                       32405074

PMC7284243 241. Letter-to-the-Editor: Alternative Interpretation to the Findings Reported in Visualization of SARS-CoV-2 Virus Invading the Human Placenta Using Electron Microscopy.

Am J Obstet Gynecol 2020; ä (ä): ä

*32533928*
                       32533928

PMC7205635 242. Detection of SARS-COV-2 in Placental and Fetal Membrane Samples.

Am J Obstet Gynecol MFM 2020; ä (ä): 100133

*32391518*
                       32391518

PMC7233206 243. Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth.

Am J Obstet Gynecol MFM 2020; ä (ä): 100145

*32427221*
                       32427221

PMC7250109 244. SARS-CoV-2: Naso-bronchial cytological correlations.

Am J Otolaryngol 2020; ä (ä): 102549

*32471774*
                       32471774

PMC7300503 245. Immunological environment shifts during pregnancy may affect the risk of developing severe complications in COVID-19 patients.

Am J Reprod Immunol 2020; ä (ä): e13285

*32516444*
                       32516444

PMC7183283 246. Revision narrativa sobre la respuesta inmunitaria frente a coronavirus: descripcion general, aplicabilidad para SARS-COV-2 e implicaciones terapeuticas.

An Pediatr (Barc) 2020; ä (ä): ä

*32439309*
                       32439309

PMC7271838 247. Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.

Anaesth Crit Care Pain Med 2020; ä (ä): ä

*32505756*
                       32505756

PMC7271846 248. Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.

Anaesth Crit Care Pain Med 2020; ä (ä): ä

*32505755*
                       32505755

PMC7307129 249. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.

Andrology 2020; ä (ä): ä

*32526061*
                       32526061

PMC7288784 250. Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients.

Anesth Analg 2020; ä (ä): ä

*32502135*
                       32502135

PMC7250589 251. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.

Angiogenesis 2020; ä (ä): ä

*32458111*
                       32458111

PMC7227180 252. Plasma CRP level is positively associated with the severity of COVID-19.

Ann Clin Microbiol Antimicrob 2020; 19 (1): 18

*32414383*
                       32414383

PMC7182529 253. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.

Ann Diagn Pathol 2020; 46 (ä): 151530

*32387855*
                       32387855

PMC7253229 254. Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19.

Ann Hematol 2020; ä (ä): ä

*32462329*
                       32462329

PMC7270513 255. Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy-a case report.

Ann Hematol 2020; ä (ä): ä

*32500224*
                       32500224

PMC7266734 256. Hematological findings in coronavirus disease 2019: indications of progression of disease.

Ann Hematol 2020; ä (ä): ä

*32495027*
                       32495027

PMC7289627 257. SARS-CoV-2 infection in children with febrile neutropenia.

Ann Hematol 2020; ä (ä): ä

*32529285*
                       32529285

PMC7288620 258. Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection.

Ann Hematol 2020; ä (ä): ä

*32529284*
                       32529284

PMC7205481 259. Signals of Th2 immune response from COVID-19 patients requiring intensive care.

Ann Hematol 2020; 99 (6): 1419-1420

*32382776*
                       32382776

PMC7238400 260. Microvascular alterations in patients with SARS-COV-2 severe pneumonia.

Ann Intensive Care 2020; 10 (1): 60

*32436075*
                       32436075

PMC7266128 261. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children.

Ann Intensive Care 2020; 10 (1): 69

*32488505*
                       32488505

PMC7224607 262. Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report.

Ann Intern Med 2020; ä (ä): ä

*32422085*
                       32422085

PMC7299653 263. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort.

Ann Rheum Dis 2020; ä (ä): ä

*32527868*
                       32527868

PMC7210193 264. A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection.

Ann Transl Med 2020; 8 (7): 481

*32395525*
                       32395525

PMC7219369 265. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

Antiviral Res 2020; 179 (ä): 104820

*32405117*
                       32405117

PMC7260490 266. SARS-CoV-2-A Tough Opponent for the Immune System.

Arch Med Res 2020; ä (ä): ä

*32532524*
                       32532524

PMC7247499 267. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2.

Arch Med Res 2020; ä (ä): ä

*32493627*
                       32493627

PMC7242954 268. Defective Anti-oxidant System: An Aggravating Factor for COVID-19 Patients Outcome?

Arch Med Res 2020; ä (ä): ä

*32471702*
                       32471702

PMC7241376 269. Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.

Arch Med Res 2020; ä (ä): ä

*32471703*
                       32471703

PMC7225698 270. COVID-19 and Dysfunctional Endothelium: The Mexican Scenario.

Arch Med Res 2020; ä (ä): ä

*32419712*
                       32419712

PMC7289093 271. Molecular mimicry may explain multi-organ damage in COVID-19.

Autoimmun Rev 2020; ä (ä): 102591

*32535095*
                       32535095

PMC7289100 272. Covid-19 and autoimmunity.

Autoimmun Rev 2020; ä (ä): 102597

*32535093*
                       32535093

PMC7221370 273. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.

Biochem Biophys Res Commun 2020; 527 (3): 702-708

*32410735*
                       32410735

PMC7261073 274. The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway.

Biochimie 2020; ä (ä): ä

*32485205*
                       32485205

PMC7258854 275. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention.

Biochimie 2020; 175 (ä): 93-98

*32479856*
                       32479856

PMC7258806 276. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.

Biomed Pharmacother 2020; 128 (ä): 110296

*32480226*
                       32480226

PMC7227559 277. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.

Blood Rev 2020; ä (ä): 100707

*32425294*
                       32425294

PMC7272899 278. Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient.

Br J Dermatol 2020; ä (ä): ä

*32407552*
                       32407552

PMC7307071 279. Haemophagocytosis in bone marrow aspirates in patients with COVID-19.

Br J Haematol 2020; ä (ä): ä

*32529634*
                       32529634

PMC7307063 280. Secondary HLH is uncommon in severe COVID-19.

Br J Haematol 2020; ä (ä): ä

*32526046*
                       32526046

PMC7241329 281. Do matrix metalloproteases mediate the SARS-CoV-2-related damage to the central nervous system?

Brain Behav Immun 2020; ä (ä): ä

*32446945*
                       32446945

PMC7245198 282. The role of IgA in COVID-19.

Brain Behav Immun 2020; 87 (ä): 182-183

*32454136*
                       32454136

283. COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination.

Brain Sci 2020; 10 (6): ä

*32512702*
                       32512702

PMC7205692 284. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.

Cell 2020; ä (ä): ä

*32479746*
                       32479746

PMC7254001 285. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.

Cell 2020; ä (ä): ä

*32492406*
                       32492406

PMC7227586 286. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Cell 2020; 181 (5): 1036-1045.e9

*32416070*
                       32416070

PMC7252096 287. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.

Cell 2020; 181 (5): 1016-1035.e19

*32413319*
                       32413319

PMC7250779 288. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.

Cell 2020; ä (ä): ä

*32526206*
                       32526206

PMC7242921 289. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.

Cell 2020; ä (ä): ä

*32526208*
                       32526208

PMC7241398 290. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.

Cell 2020; ä (ä): ä

*32516571*
                       32516571

PMC7237901 291. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.

Cell 2020; ä (ä): ä

*32473127*
                       32473127

PMC7231725 292. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.

Cell 2020; ä (ä): ä

*32425270*
                       32425270

PMC7218368 293. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.

Cell 2020; 181 (6): 1194-1199

*32405102*
                       32405102

PMC7278239 294. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19).

Cell Death Differ 2020; ä (ä): ä

*32514047*
                       32514047

PMC7276960 295. The inhibition of IL-2/IL-2R gives rise to CD8(+) T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.

Cell Death Dis 2020; 11 (6): 429

*32513989*
                       32513989

PMC7248455 296. ACE2 expression and sex disparity in COVID-19.

Cell Death Discov 2020; 6 (ä): 37

*32499922*
                       32499922

PMC7250783 297. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis.

Cell Host Microbe 2020; ä (ä): ä

*32485164*
                       32485164

PMC7237895 298. The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?

Cell Host Microbe 2020; 27 (6): 863-869

*32464098*
                       32464098

PMC7227451 299. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.

Cell Mol Immunol 2020; 17 (6): 621-630

*32415260*
                       32415260

PMC7214859 300. Is aberrant CD8+ T cell activation by hypertension associated with cardiac injury in severe cases of COVID-19?

Cell Mol Immunol 2020; 17 (6): 675-676

*32398804*
                       32398804

PMC7231734 301. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.

Cell Rep 2020; 31 (9): 107725

*32426212*
                       32426212

PMC7260489 302. Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2.

Cell Rep 2020; 31 (11): 107774

*32531208*
                       32531208

PMC7250245 303. On barring the vascular gateway against severe COVID-19 disease.

Cell Stress Chaperones 2020; ä (ä): ä

*32458383*
                       32458383

PMC7271958 304. COVID-19 and heme oxygenase: novel insight into the disease and potential therapies.

Cell Stress Chaperones 2020; ä (ä): ä

*32500379*
                       32500379

PMC7245315 305. An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19.

Clin Chim Acta 2020; 508 (ä): 213-216

*32454047*
                       32454047

PMC7224669 306. The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?

Clin Chim Acta 2020; 508 (ä): 122-129

*32417210*
                       32417210

PMC7219428 307. Decreased T cell populations contribute to the increased severity of COVID-19.

Clin Chim Acta 2020; 508 (ä): 110-114

*32405080*
                       32405080

PMC7282743 308. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients.

Clin Chim Acta 2020; 509 (ä): 135-138

*32531257*
                       32531257

PMC7283076 309. Cytokine Storm Induced by SARS-CoV-2.

Clin Chim Acta 2020; ä (ä): ä

*32531256*
                       32531256

PMC7246018 310. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.

Clin Immunol 2020; 217 (ä): 108480

*32461193*
                       32461193

PMC7278649 311. A plea for the pathogenic role of immune complexes in severe Covid-19.

Clin Immunol 2020; 217 (ä): 108493

*32526273*
                       32526273

PMC7239202 312. An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19.

Clin Infect Dis 2020; ä (ä): ä

*32407466*
                       32407466

PMC7245297 313. Correlation between viral RNA shedding and serum antibodies in individuals with coronavirus disease 2019.

Clin Microbiol Infect 2020; ä (ä): ä

*32454188*
                       32454188

PMC7242209 314. SARS-CoV-2 persisted in lung tissue despite disappearance in other clinical samples.

Clin Microbiol Infect 2020; ä (ä): ä

*32447048*
                       32447048

PMC7274099 315. COVID 19 and brain crosstalks.

Clin Neurol Neurosurg 2020; 196 (ä): 105991

*32526483*
                       32526483

PMC7300732 316. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.

FASEB J 2020; ä (ä): ä

*32525600*
                       32525600

PMC7293426 317. Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19).

Infection 2020; ä (ä): ä

*32535877*
                       32535877

318. Placental Pathology in COVID-19.

Am J Clin Pathol 2020; ä (ä): ä

*32533690*
                       32533690

319. Reply: COVID-19 Lung Injury and "Typical" ARDS: The Danger of Presumed Equivalency.

Ann Am Thorac Soc 2020; ä (ä): ä

*32432897*
                       32432897

320. Respiratory Mechanics and Gas Exchange in COVID-19 Associated Respiratory Failure.

Ann Am Thorac Soc 2020; ä (ä): ä

*32432896*
                       32432896

321. COVID-19 Lung Injury and "Typical" ARDS: The Danger of Presumed Equivalency.

Ann Am Thorac Soc 2020; ä (ä): ä

*32432895*
                       32432895

322. Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?

Ann Rheum Dis 2020; ä (ä): ä

*32434816*
                       32434816

323. Is Albumin Predictor of Mortality in COVID-19?

Antioxid Redox Signal 2020; ä (ä): ä

*32524832*
                       32524832

324. C1-INH and the contact system in COVID-19.

Br J Haematol 2020; ä (ä): ä

*32531085*
                       32531085

325. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.

Clin Chim Acta 2020; ä (ä): ä

*32533986*
                       32533986

326. Antibody-dependent enhancement and COVID-19: Moving toward acquittal.

Clin Immunol 2020; 217 (ä): 108496

*32526272*
                       32526272

327. Tuberculosis and type 2 Diabetes Mellitus: an inflammatory danger signal in the time of COVID-19.

Clin Infect Dis 2020; ä (ä): ä

*32533824*
                       32533824

328. C3 polymorphisms represent an important immunological confounder on the spread and outcome of COVID-19.

Eur J Prev Cardiol 2020; ä (ä): 2047487320931999

*32517505*
                       32517505

329. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics.

Glycobiology 2020; ä (ä): ä

*32518941*
                       32518941

330. How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?

Immunol Lett 2020; 224 (ä): 28-29

*32522666*
                       32522666

331. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?

Infect Genet Evol 2020; ä (ä): 104417

*32526370*
                       32526370

332. Elevated expression of ACE2 in tumor-adjacent normal tissues of cancer patients.

Int J Cancer 2020; ä (ä): ä

*32525565*
                       32525565

PMC7190003 333. Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Integr Med (Encinitas) 2020; 19 (Suppl 1): 8-35

*32425712*
                       32425712

334. Introductory histopathologic findings may shed light on COVID19 pediatric hyperinflammatory shock syndrome.

J Eur Acad Dermatol Venereol 2020; ä (ä): ä

*32535977*
                       32535977

335. Early Insights into Immune Responses during COVID-19.

J Immunol 2020; ä (ä): ä

*32513850*
                       32513850

336. ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19.

J Infect Dis 2020; ä (ä): ä

*32526012*
                       32526012


{{tp|p=32515982|t=2020. H2S as a potential defence against COVID-19?|pdf=|usr=}}
{{tp|p=32526026|t=2020. Hypersegmented granulocytes and COVID-19 infection.|pdf=|usr=}}

337. H2S as a potential defence against COVID-19?

Am J Physiol Cell Physiol 2020; ä (ä): ä

*32515982*
                       32515982

PMC7290095 338. Hypersegmented granulocytes and COVID-19 infection.

Blood 2020; 135 (24): 2196

*32526026*
                       32526026